Vincerx Pharma Presents Positive Preliminary Phase 1 Data for VIP236 and Updates on Pipeline ...

VIP236 demonstrated positive signs of clinical activity, including tumor reduction, and an improved safety profile in heavily pretreated patients with metastatic solid tumors

Related Keywords

Palo Alto ,California ,United States ,Germany ,American ,Totyana Simien ,Gabriela Jairala ,Ahmed Hamdy ,Vivek Subbiah ,Raquel Izumi ,Exchange Commission ,Securities Exchange ,Nasdaq ,Linkedin ,Vincerx Pharma Inc ,European Hematology Association ,American Association For Cancer Research ,American Association ,Cancer Research ,Annual Meeting ,Chief Executive Officer ,Hematology Association ,Chief Operating Officer ,Early Phase Drug Development ,Sarah Cannon Research Institute ,Hematology Association Annual Meeting ,Vincerx Investor Page ,Versaptx Platform ,Vincerx Pharma ,Securities Act ,Securities Exchange Act ,Region ,